Burrill & Company
Biotech endures through choppy month
Published in Healthcare Mergers, Acquisitions and Ventures Week, May 1st, 2004
Despite good earnings representing solid performance in a number of life sciences subsectors, it was not enough to overcome the general market malaise that infected both the NASDAQ and the Dow Jones Industrial Average.
"It appears that biotech successes were not enough," said G. Steven Burrill, CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. "Amgen had big earnings, solid revenue growth, and laid out its impressive development plans and pipeline, only to have its price drop 5% on the news. Ultimately, it purchased Tularik...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- AMDL, Inc.
Cancer diagnostics company reports 101% increase in revenue - Abortion
Doctor testifies that banned type of abortion needs more study - Adoption Issues
Oklahoma health department to issue birth certificates to same-sex couples - Agendia BV
Pharmacogenomics firm closes series A financing round - Alliance for Lupus Research
Lupus group announces $6.7M in research grants - Alta Partners
Venture capital fund closes $475M in life sciences funds - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
